newsfilter
← Latest News
PR Newswire·

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patientsMaintains strong financial position with approximately $37.5 million